Integral Diagnostics

MRI Licensing And Lung Screening Will Expand Imaging Potential

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Apr 25

Updated

27 Aug 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-19.7%

-1.6%

-19.7%

-1.6%

You can edit this narrative until Aug 27 11:25 AM. Then, changes will post as Updates.

Author's Valuation

AU$3.3628.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 27 Aug 25

Fair value Increased 7.79%

Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.

Shared on 01 May 25

Fair value Decreased 0.64%

AnalystConsensusTarget Fair Value

AU$3.36

28.3% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

9.74%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.70%

Calculation

AU$68.04m

Earnings '28

22.31x

PE Ratio '28

AU$1.52b

Market Cap '28

AU$1.52b

Market Cap '28

374.05m

No. shares '28

AU$4.06

Share Price '28

AU$4.06 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$3.36

Fair Value '25